The Use of Proton Pump Inhibitors in Intensive Care Units
By:
References
- 1. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002; 30(6 ): S373-8.
- 2. Thorsen K, Søreide JA, Kvaløy JT, Glomsaker T, Søreide K. Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality. World J Gastroenterol. 2013; 19(3): 347-54.
- 3. Abraham E. Acid suppression in a critical care environment: state of the art and beyond. Crit Care Med. 2002; 30(6 Suppl): S349-50.
- 4. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Critical Care Trials Groups. N Engl J Med 1994; 330:397-81.
- 5. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002; 30(6 Suppl): S351-5.
- 6. Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med. 2002; 30(6 Suppl): S365-8.
- 7. Jaspersen D, Koerner T, Schorr W, et al: Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc. 1995; 41:5–7.
- 8. Halm U, Halm F, Thein D, et al: Helicobacter pylori infection: A risk factor for upper gastrointestinal bleeding after cardiac surgery? Crit Care Med. 2000; 28:110-13.
- 9. Simoens M, Gevers AM, Rutgeerte P: Endoscopic therapy for upper gastrointestinal hemorrhage: A state of the art. Hepatogastroenterology. 1999; 46:737–45.
- 10. Savides TJ, Jensen DM: Therapeutic endoscopy for nonvariceal gastrointestinal bleeding. Gastroenterol Clin North Am. 2000; 29:465-87.
- 11. Berenholtz S: Management of upper gastrointestinal hemorrhage. Resident Reporter. 1999; 4:112-18.
- 12. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38(3):316-321.
- 13. Richter-Schrag H-J, Glatz T, Walker C, Fischer A, Thimme R. First-line endoscopic treatment with overthe-scope clips significantly improves the primary failure and rebleeding rates in high-risk gastrointestinal bleeding: A single-center experience with 100 cases. Am J Gastroenterol. 2016;22(41):9162-9171.
- 14. Mokhtare M, Bozorgi V, Agah S, et al. Comparison of Glasgow-Blatchford score and full Rockall score systems to predict clinical outcomes in patients with upper gastrointestinal bleeding. Clin Exp Gastroenterol. 2016; 9:337-343.
- 15. Barer D, Ogilvie A, Henry D, et al: Cimetidine and tranexamic acid in the treatment of acute upper gastrointestinal-tract bleeding. N Engl J Med 1983; 308:1571–1575.
- 16. Walt RP, Cottrell J, Mann SG, et al: Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340:143-47.
- 17. Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Scand J Gastroenterol. 1997; 32:320-27.
- 18. Lau JY, Sung JJ, Lee KKC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000; 343:10-16.
- 19. Ganser AL, Forte JG. K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochem Biophys Acta. 1973; 307: 169-80.
- 20. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005; 14:411-21.
- 21. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: The H+, K+- ATPase. Annu Rev Pharmacol Toxicol. 1995; 35:277–305.
- 22. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005; 59:709-15.
- 23. Ang TL, Fock KM. Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 2006; 21(Suppl 5): S125-28.
- 24. Vakil N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 19:1041-49.
- 25. Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not affect risk for Clostridium difficile infection in the intensive care unit. Am J Gastroenterol. 2016;111(11):1641-48.
- 26. Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Critical Care. 2014;18(6):714.
- 27. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton Pump Inhibitors and Risk for Recurrent Clostridium Difficile Infection Among Inpatients. Am J Gastroenterol. 2013;108(11):1794-801.
- 28. Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med. 1996; 69:233–243.
- 29. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005; 108:294–307.
- 30. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S, Hasselgren G. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5:1385-391.
- 31. Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-4.
- 32. Harty RF, Ancha HB. Stress ulcer bleeding. Curr Treat Options Gastroenterol. 2006; 9: 157-66.
- 33. Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse. 2006; 26: 18-28.
- 34. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008; 135: 41-60.
- 35. Sesler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care 2007; 18: 119-26.
- 36. Spirt MJ. Stress-related mucosal disease: risk factors and prophylactic therapy. Clin Ther. 2004; 26: 197-213.
- 37. Constantin VD, Paun S, Ciofoaia VV, Budu V, Socea B. Multimodal management of upper gastrointestinal bleeding caused by stress gastropathy. J Gastrointestin Liver Dis. 2009; 18(3): 279-84.
- 38. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139(1): 93-101.
- 39. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med. 2002; 30(6): S369-72.
- 40. Balsells E, Filipescu T, Kyaw MH, Wiuff C, Campbell H, Nair H. Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations. J Glob Health. 2016; 6(2): 020410.
Language: English
Page range: 195 - 200
Submitted on: Feb 9, 2017
Accepted on: Mar 19, 2017
Published on: Sep 20, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2022 Aleksandar Cvetkovic, Marko Spasic, Mladen Pavlovic, Danijela Cvetkovic, Bojan Stojanovic, Srdjan Ninkovic, Jasna Jevdjic, Dragan Canovic, Bojan Milosevic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.